Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Tarsus Pharmaceuticals, Inc. (TARS : NSDQ)

• Company Description    Tarsus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutic candidates to address ophthalmic conditions. The company's product candidate consist TP-03 which is in clinical stage. Tarsus Pharmaceuticals Inc. is based in IRVINE, Calif. Number of Employees: 370

• Price / Volume Information    Yesterday's Closing Price: $58.66 Daily Weekly Monthly 20 Day Moving Average: 1,436,954 shares Shares Outstanding: 43.02 (millions) Market Capitalization: $2,523.78 (millions) Beta: 0.50 52 Week High: $85.25 52 Week Low: $38.51 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -6.77% -7.50% 12 Week -7.80% -10.06% Year To Date -28.36% -33.83%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 15440 LAGUNA CANYON ROAD SUITE 160 - IRVINE,CA 92618 USA ph: 949-418-1801 fax: - ir@tarsusrx.com http://www.tarsusrx.com

• General Corporate Information    Officers Bobak Azamian - President; Chief Executive Officer and Chairman Jeffrey Farrow - Chief Financial Officer and Chief Strategy Officer Bhaskar Chaudhuri - Director Andrew Goldberg - Director Katherine Goodrich - Director Peer Information Tarsus Pharmaceuticals, Inc. (CORR.) Tarsus Pharmaceuticals, Inc. (RSPI) Tarsus Pharmaceuticals, Inc. (CGXP) Tarsus Pharmaceuticals, Inc. (BGEN) Tarsus Pharmaceuticals, Inc. (GTBP) Tarsus Pharmaceuticals, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 87650L103 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/05/26 Share - Related Items Shares Outstanding: 43.02 Most Recent Split Date: (:1) Beta: 0.50 Market Capitalization: $2,523.78 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.99 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.04 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/05/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 7.23 Price/Cash Flow: - Price / Sales: 4.72 EPS Growth vs. Year Ago Period: 75.00% vs. Previous Quarter: 20.00% Sales Growth vs. Year Ago Period: 106.87% vs. Previous Quarter: 6.85% ROE 06/30/26 - - 03/31/26 - -14.19 12/31/25 - -19.63 ROA 06/30/26 - - 03/31/26 - -8.89 12/31/25 - -12.70 Current Ratio 06/30/26 - - 03/31/26 - 3.74 12/31/25 - 3.85 Quick Ratio 06/30/26 - - 03/31/26 - 3.71 12/31/25 - 3.82 Operating Margin 06/30/26 - - 03/31/26 - -9.02 12/31/25 - -14.72 Net Margin 06/30/26 - - 03/31/26 - -9.02 12/31/25 - -14.72 Pre-Tax Margin 06/30/26 - - 03/31/26 - -8.20 12/31/25 - -14.26 Book Value 06/30/26 - - 03/31/26 - 8.11 12/31/25 - 8.09 Inventory Turnover 06/30/26 - - 03/31/26 - 8.38 12/31/25 - 8.30 Debt-to-Equity 06/30/26 - - 03/31/26 - 0.21 12/31/25 - 0.21 Debt-to-Capital 06/30/26 - - 03/31/26 - 17.22 12/31/25 - 17.42

Powered by Zacks Investment Research ©